Cryptococcosis is one of the most devastating human fungal infections. Despite its impact, none of the standard antifungals were developed after 1990. New, improved, less toxic, affordable and widely available treatment is, therefore, imperative. Areas covered: This review offers an insight into technological developments for cryptococcosis disclosed in patent literature. From a broad search of patent documents claiming cryptococcosis treatment and having earliest priority between 1995 and 2015, we selected and summarized compounds/molecules (i) revealed in documents disclosing in vivo activity against Cryptococcus spp. or (ii) found in the pipeline of companies that appeared as assignees in our patent search. This information was complemented with data on compounds under development for this indication from the database Integrity (Clarivate Analytics). Expert opinion: This review demonstrates that drug development against cryptococcosis is discrete. However, it also shows that the existing development is not focused on a single class of molecules, but on different types of molecules with distinct fungal targets, reflecting the complexity of generating novel anti-cryptococcal tools. Given the intrinsic difficulties and high costs of drug development and the evident market failure in this field, we consider drug repurposing the most promising avenue for cryptococcosis treatment.
BACKGROUND Cryptococcosis is one of the most devastating fungal infections in humans. Despite the disease’s clinical importance, current therapy is based on limited antifungals that are either toxic, inefficient, unavailable worldwide, or that quickly lead to resistance.OBJECTIVES The goal of this study was to provide insight into the future of cryptococcosis treatment by describing the patent scenario in this field.METHODS We identified and analysed patent documents revealing compounds with anti-cryptococcal activity supported by experimental evidence.FINDINGS Patenting in this field has been historically low, with an overall tendency of increase since 2012. Most applications are single filings, suggesting that they do not encompass strategic inventions requiring broad protection. Research and development essentially took place in China and the United States, which also represent the main countries of protection. Both academic and corporate institutions contributed to patenting in this field. Universities are the leading actors, with the highest patent family counts.CONCLUSION The low number of patents in this field indicates that efforts to mitigate the unmet needs for cryptococcosis treatment remain insufficient. Without investment to drive research and innovation, patients will likely continue to face inadequate assistance. Given the current scenario characterised by poor funding and low interest for technological development, drug repurposing may be the best alternative for cryptococcosis treatment.
Prospecting studies provide an overview of patent documents and scientific literature of a particular technology, being relevant in policy discussions, research strategy planning or technology transfer. The Escritório de Inovação-EI (Innovation Office), of the Centro de Desenvolvimento Tecnológico em Saúde-CDTS, proposed to carry out prospecting studies to strengthen internal research projects conducted mainly by graduate students. Objective: The present study aimed to provide a methodology to perform an analysis of the scientific and patent literature for postgraduation research projects. The main objective was to give information about the state-of-the-art of the technology, providing inputs for correct decision making, taking into account technological development and innovation. Methodology: The project "Functional characterization of a panel of tumor-specific aptamers for triple negative breast cancer" served as a pilot. Patent document searches were carried out in September 2018 using the database Orbit Intelligence. We searched for documents containing the words "aptamer* and breast cancer" in their title, abstract, or claims and classified as A61 (human needs-medical or veterinary science; hygiene) by IPC. Regarding the scientific literature, three different databases were used: Web of Science, Scopus and Pubmed with the same key words for patent search. Parts of the study were carried out jointly with the student. Results: The search resulted in 653 patent families and 753 different scientific papers. Since the first patent filing in 1995, there has been a notable increase in the number of patent deposits involving aptamer technology and its application to breast cancer, with a peak in 2015. Through the analysis of the countries where assignees sought protection for their inventions, it is possible to infer that the markets of greatest interest in this technology are USA, Europe and China. The majority of the patent documents analyzed is related to the use of aptamers for therapy against breast cancer. Among the analyzed scientific articles, an expansion of the studies involving this technological area was also observed, with most of the research centers located in the USA and China. Through self-correlation analysis, it was observed some networks of interaction between the affiliations of the first authors of the studies analyzed. In relation to Brazil, attention is drawn to the position of the University of the State of Rio de Janeiro as a bridge between national and international institutions. Conclusion: The prospective analysis can contrisute to many scientific and economical aspects in the research and technological development of aptamers and their use for breast cancer. The designed methodology generates studies suitable to support graduate projects, avoiding waste or replication of scientific research, mainly at public institutions, and can promote the literacy of postgraduation students.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.